DICE(Delisted)
DICE TherapeuticsยทNASDAQ
--
--(--)
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About DICE
Dice Therapeutics, Inc.
A biopharmaceutical company that designs and develops oral therapeutic candidates to treat chronic diseases
400 East Jamie Court, Suite 300, South San Francisco, California 94080
--
DICE Therapeutics, Inc., was incorporated in Delaware on August 14, 2013. The Company is a biopharmaceutical company that leverages its proprietary technology platform to build a portfolio of novel oral therapies for the treatment of chronic diseases in immunology and other therapeutic areas. The company initially focused on developing oral therapies against well-proven targets in immunology, with the goal of achieving the same effect as the systemic biological counterpart, which has proven to date to have the greatest therapeutic benefit in these disease areas.
Company Financials
EPS
DICE has released its 2023 Q1 earnings. EPS was reported at -0.54, versus the expected -0.58, beating expectations. The chart below visualizes how DICE has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
Related Symbols
No Data
You can ask Aime
No Data
